Pozanicline (ABT-089) is a drug developed by Abbott which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective binding primarily to the α4β2 and also α6β2 subtypes. It has nootropic and neuroprotective effects and animal studies suggested that it might be useful for the treatment of ADHD.
This page contains content from the copyrighted Wikipedia article "Pozanicline"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
